Inhibition of lymphokine-activated killer T-cell-originated protein kinase (TOPK) (64% at 400 μg/mL) and EGF-downstream signaling. ↓ Tumor growth 72% at 50 mg/kg. This evidence concerns the gene EGF and neoplasm.